Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report)’s share price dropped 9.6% during trading on Wednesday . The stock traded as low as $18.82 and last traded at $18.94. Approximately 147,571 shares were traded during trading, a decline of 46% from the average daily volume of 270,993 shares. The stock had previously closed at $20.96.
Analysts Set New Price Targets
DMRA has been the subject of several recent analyst reports. UBS Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They set a “buy” rating and a $45.00 price target for the company. TD Cowen initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday. They set a “buy” rating for the company. Wedbush started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Thursday, May 28th. They set an “outperform” rating and a $35.00 price target for the company. Evercore started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price target for the company. Finally, Guggenheim restated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.
Check Out Our Latest Analysis on Damora Therapeutics, Inc. Common Stock
Damora Therapeutics, Inc. Common Stock Trading Down 6.3%
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). On average, equities analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.1 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $40,000. Virtu Financial LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $49,000. Two Sigma Investments LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $76,000. Connective Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $100,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $266,000. Institutional investors and hedge funds own 14.20% of the company’s stock.
Damora Therapeutics, Inc. Common Stock Company Profile
Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.
Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.
Featured Stories
- Five stocks we like better than Damora Therapeutics, Inc. Common Stock
- Palantir’s AIPCon Shows Why Customers Are Fueling the Bull Case
- Chewy’s Growth Engine Is Stronger Than the Market Thinks
- Nebius Group’s £1.7 Billion UK Expansion Fuels Bullish Case Despite the Pullback
- An Analyst Just Raised Tesla’s Price Target by 227%—Here’s Why
Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
